Navigation Links
John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Date:3/5/2008

ROCHESTER, N.Y., March 5 /PRNewswire/ -- Vaccinex, Inc. announced today that Dr. John E. Leonard has joined its Scientific Advisory Board, and will be actively involved in the strategic planning and execution of the company's therapeutic antibody development programs.

Dr. Leonard has over 20 years of experience at Idec and Biogen Idec, having held Senior Director level positions in Regulatory Affairs, Quality, Project Management and Product Development, and Vice President level positions in Quality, Product Development and Program Management.

Dr. Maurice Zauderer, Vaccinex's President and CEO, remarked: "As we advance our lead therapeutic antibody candidates into pre-clinical and clinical development, we are delighted that John has agreed to join our SAB and take an active role in advising the company on our technical development plans and pipeline strategies. With his extensive background in antibody drug development, and his first-hand experience in the development of Rituxan(R), Zevalin(R) and most recently Tysabri(R), he will be an invaluable resource to our in-house development team."

"I am very pleased to join Vaccinex's Scientific Advisory Board. With the company's novel ActivMAb(R) antibody discovery technology and its emerging pipeline of lead antibody candidates, I think Vaccinex is well positioned to advance the development of several innovative therapies in the areas of cancer, autoimmune disease, and inflammation," said Dr. Leonard.

Dr. Leonard received his BS in Chemistry and MS in Biochemistry from California State University, Long Beach, and his Ph.D. in Biochemistry from the University of California, Riverside. He is a retired U.S. Army Colonel serving most recently in the Medical Services Corps.

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit http://www.vaccinex.com.

Additional Information

Rituxan(R) and Zevalin(R) are registered trademarks of Biogen Idec. Tysabri(R) is a registered trademark of Elan Pharmaceuticals.

Press Contact

Raymond E. Watkins, Vice President of Operations & Officer

Vaccinex, Inc.

+1.585.271.2700 Ext. 105

E-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
2. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
3. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
4. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
5. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
6. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
7. TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs
8. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
9. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
10. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
11. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Wisconsin (PRWEB) , ... August 15, 2017 , ... ... a new family of 6” modular downlights designed to stay tightly sealed and ... including areas where damp and wet location listings just aren't enough, such as: ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... interconnect using USB or PCI Express, announced the release of SYZYGY™, a new ... to satisfy the need for a compact, low cost, low pin-count, high-performance connectivity ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is ... more natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave ... established manufacturing presence and know-how of Biorigin will allow us to bring truly ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... Okyanos Center ... take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, ... is required. , With oversight from the Ministry of Health’s National Stem Cell ...
Breaking Biology Technology:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):